The Claim
AMG 145 induces dose-dependent reductions in apolipoprotein B (ApoB) of up to 59% in hypercholesterolemic adults who are on statin therapy, suggesting a broad suppression of atherogenic lipoprotein particles that extends beyond low-density lipoprotein cholesterol (LDL-C) alone.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
A drug called AMG 145 can lower a harmful blood protein linked to heart disease by up to 59% in people with high cholesterol who are already taking statins, and it seems to do more than just lower bad cholesterol.
See the scientific wording
AMG 145 causes dose-dependent reductions in apolipoprotein B (ApoB) of up to 59% in hypercholesterolemic adults on statin therapy, indicating broad suppression of atherogenic lipoprotein particles beyond LDL-C alone.
What the research says
1 studyThe study tested the same drug (AMG 145) in the same group of people and found it greatly lowered bad cholesterol. While it didn’t directly measure ApoB, the results still support the idea that the drug reduces harmful particles in the blood.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.